Developing a novel in vitro Cancer-on-Chip platform to study chemotherapy and radiotherapy sensitivity in head and neck cancer patients
Not Applicable
- Conditions
- Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
- Registration Number
- CTRI/2024/02/062196
- Lead Sponsor
- Sanjiban Chakrabarty
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
locally advanced HNSCC planned for treatment with definitive radiotherapy with or without concurrent chemotherapy. For recurrent patients, locoregional persistence or recurrence following definitive radiotherapy with or without chemotherapy. Metastatic recurrence could also be included, if biopsy is feasible.
Exclusion Criteria
1) Age above 70 years,
2) Medically compromised,
3) Low performance status,
4) unwillingness to participate,
5) Unwilling/unfit for tumor directed treatment for recurrent disease.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development of a microfluidic-based platform to study radiation and drug response in ex vivo patient-derived tumor slice culture.Timepoint: 4 years.
- Secondary Outcome Measures
Name Time Method Identification of novel genes and pathways responsible for radio-resistance.Timepoint: 3 years